Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis

Inmaculada Tasset, Carmen Bahamonde, Eduardo Agüera, Cristina Conde, Antonio H. Cruz, Aleyda Pérez-Herrera, Félix Gascón, Ana I. Giraldo, María C. Ruiz, Rafael Lillo, Fernando Sánchez-López, Isaac Túnez

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage. Methods: Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated. Results: Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels. Conclusion: These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.

Original languageEnglish (US)
Pages (from-to)624-631
Number of pages8
JournalPharmacological Reports
Volume65
Issue number3
StatePublished - 2013
Externally publishedYes

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Biomarkers
Peroxidase
Multiple Sclerosis
Glutathione
Vascular Cell Adhesion Molecule-1
Glutathione Peroxidase
Granulocytes
Superoxide Dismutase
Natalizumab
Neutrophils
Antioxidants
Monoclonal Antibodies
Guidelines
Therapeutics
Serum
Proteins

Keywords

  • Adhesion molecules
  • Multiple sclerosis
  • Natalizumab
  • Nrf2
  • Oxidative stress

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tasset, I., Bahamonde, C., Agüera, E., Conde, C., Cruz, A. H., Pérez-Herrera, A., ... Túnez, I. (2013). Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. Pharmacological Reports, 65(3), 624-631.

Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. / Tasset, Inmaculada; Bahamonde, Carmen; Agüera, Eduardo; Conde, Cristina; Cruz, Antonio H.; Pérez-Herrera, Aleyda; Gascón, Félix; Giraldo, Ana I.; Ruiz, María C.; Lillo, Rafael; Sánchez-López, Fernando; Túnez, Isaac.

In: Pharmacological Reports, Vol. 65, No. 3, 2013, p. 624-631.

Research output: Contribution to journalArticle

Tasset, I, Bahamonde, C, Agüera, E, Conde, C, Cruz, AH, Pérez-Herrera, A, Gascón, F, Giraldo, AI, Ruiz, MC, Lillo, R, Sánchez-López, F & Túnez, I 2013, 'Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis', Pharmacological Reports, vol. 65, no. 3, pp. 624-631.
Tasset I, Bahamonde C, Agüera E, Conde C, Cruz AH, Pérez-Herrera A et al. Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. Pharmacological Reports. 2013;65(3):624-631.
Tasset, Inmaculada ; Bahamonde, Carmen ; Agüera, Eduardo ; Conde, Cristina ; Cruz, Antonio H. ; Pérez-Herrera, Aleyda ; Gascón, Félix ; Giraldo, Ana I. ; Ruiz, María C. ; Lillo, Rafael ; Sánchez-López, Fernando ; Túnez, Isaac. / Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. In: Pharmacological Reports. 2013 ; Vol. 65, No. 3. pp. 624-631.
@article{5b71ebeea15f4f51b7686d53542291ed,
title = "Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis",
abstract = "Background: Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage. Methods: Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated. Results: Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels. Conclusion: These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.",
keywords = "Adhesion molecules, Multiple sclerosis, Natalizumab, Nrf2, Oxidative stress",
author = "Inmaculada Tasset and Carmen Bahamonde and Eduardo Ag{\"u}era and Cristina Conde and Cruz, {Antonio H.} and Aleyda P{\'e}rez-Herrera and F{\'e}lix Gasc{\'o}n and Giraldo, {Ana I.} and Ruiz, {Mar{\'i}a C.} and Rafael Lillo and Fernando S{\'a}nchez-L{\'o}pez and Isaac T{\'u}nez",
year = "2013",
language = "English (US)",
volume = "65",
pages = "624--631",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "3",

}

TY - JOUR

T1 - Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis

AU - Tasset, Inmaculada

AU - Bahamonde, Carmen

AU - Agüera, Eduardo

AU - Conde, Cristina

AU - Cruz, Antonio H.

AU - Pérez-Herrera, Aleyda

AU - Gascón, Félix

AU - Giraldo, Ana I.

AU - Ruiz, María C.

AU - Lillo, Rafael

AU - Sánchez-López, Fernando

AU - Túnez, Isaac

PY - 2013

Y1 - 2013

N2 - Background: Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage. Methods: Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated. Results: Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels. Conclusion: These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.

AB - Background: Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage. Methods: Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated. Results: Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels. Conclusion: These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.

KW - Adhesion molecules

KW - Multiple sclerosis

KW - Natalizumab

KW - Nrf2

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84884495677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884495677&partnerID=8YFLogxK

M3 - Article

C2 - 23950585

AN - SCOPUS:84884495677

VL - 65

SP - 624

EP - 631

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 3

ER -